NCT07406035

A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis

A Randomized, Placebo- and Active Drug-Controlled, Double-Blind, Multicenter, Parallel-Group Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 156 (estimated)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study is a marketing-oriented clinical trial of TQH3906 Capsules. A total of 156 participants are planned to be enrolled, aiming to evaluate the dose-effect relationship of TQH3906 versus placebo in the treatment of active Psoriatic Arthritis (PsA) at Week 12, with the proportion of participants achieving an American College of Rheumatology 20% (ACR20) Improvement Criteria (ACR20) response at Week 12 as the primary endpoint.

Conditions

• Psoriatic Arthritis

Interventions

Type	Name	Description
DRUG	TQH3906 Capsule	TQH3906 is a small-molecule inhibitor of tyrosine kinase.
DRUG	TQH3906 Placebo Capsule	Placebo without drug substance.
DRUG	Tofacitinib Citrate Tablet 5 mg	Tofacitinib Citrate Tablets are Janus kinase (JAK) inhibitors.

Timeline

• Start date: 2026-04-01
• Primary completion: 2027-08-01
• Completion: 2027-11-01
• First posted: 2026-02-12
• Last updated: 2026-02-12

Locations

43 sites across 1 country: China